Overview

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Merck Sharp & Dohme Corp.
Seagen Inc.
Treatments:
Brentuximab Vedotin
Dexamethasone
Gemcitabine
Pembrolizumab